Efficient generation of highly purified pancreatic islets across multiple stem cell lines
Background
Human pluripotent stem cell (hPSC)-derived pancreatic islets show significant promise for cell replacement therapies in type 1 diabetes, but the current differentiation protocols often produce heterogeneous cultures containing immature endocrine cells and unwanted non-endocrine populations. Achieving reproducible differentiation across multiple stem cell lines while maintaining endocrine purity remains a key challenge in the development of clinically relevant stem cell therapies.
Biolaminin® contribution
In this study, Wu et al. developed an optimized differentiation protocol that consistently generated functional stem cell-derived pancreatic islets (SC-islets) from eight different human pluripotent stem cell lines. Biolaminin 521 (LN-521) was utilized during two-dimensional endocrine progenitor differentiation as part of the optimized differentiation workflow. The researchers found that combining Biolaminin 521 with a shortened pancreatic progenitor stage significantly improved the generation of NKX6.1+/NEURO1+ endocrine progenitor cells, an important intermediate cell population in pancreatic endocrine development. When compared with longer differentiation conditions, the optimized LN-521 workflow increased SC-islet formation and produced a higher proportion of insulin-producing β cells.
Transitioning endocrine progenitor cells into three-dimensional aggregates further enriched endocrine populations while selectively removing proliferative and non-endocrine cells. The resulting SC-islets displayed high endocrine purity and robust glucose-responsive insulin and C-peptide secretion, demonstrating the ability of the cells to sense changes in glucose concentration and respond through regulated insulin secretion, a defining characteristic of functional pancreatic β cells. Single-cell transcriptomic analysis further confirmed the absence of detectable non-endocrine populations and revealed endocrine cell compositions consistent with mature pancreatic islets.
Clinical translation and future applications
Following intraocular transplantation into diabetic mice, the SC-islets restored glycemic control, produced human C-peptide, and continued to mature in vivo. Collectively, these findings demonstrate that Biolaminin 521 supports a robust and reproducible pancreatic differentiation workflow capable of generating highly functional SC-islets with improved endocrine purity across multiple pluripotent stem cell lines. The resulting SC-islets exhibited functional characteristics in vitro and continued to mature following transplantation, highlighting their potential of this optimized differentiation strategy for future cell therapy applications.

Talk to our team for customized support
We are here to help you in your journey.